Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)

被引：85

作者：

Ahmed-Belkacem, Abdelhakim

Pozza, Alexandre

Macalou, Sira

Perez-Victoria, Jose M.

Boumendjel, Ahcene

Di Pietro, Attilio

机构：

[1] Univ Lyon, CNRS, UMR 5086, Inst Biol & Chim Prot,IFR128, F-69367 Lyon 07, France

[2] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain

[3] Univ Grenoble 1, CNRS, UMR 5063, Dept Pharmacochim Mol, Meylan, France

来源：

ANTI-CANCER DRUGS | 2006年 / 17卷 / 03期

关键词：

ABCG2; ATP-binding cassette transporters; breast cancer resistance protein; multidrug resistance modulators; structure-activity relationships;

D O I：

10.1097/00001813-200603000-00001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer resistance protein (BCRP/ABCG2) belongs to the ATP-binding cassette (ABC) transporter superfamily. It is able to efflux a broad range of anti-cancer drugs through the cellular membrane, thus limiting their anti-proliferative effects. Due to its relatively recent discovery in 1998, and in contrast to the other ABC transporters P-glycoprotein (MDR1/ABCB1) and multidrug resistance-associated protein (MRP1/ABCC1), only a few BCRP inhibitors have been reported. This review summarizes the known classes of inhibitors that are either specific for BCRP or also inhibit the other multidrug resistance ABC transporters. Information is presented on structure-activity relationship aspects and how modulators may interact with BCRP.

引用

页码：239 / 243

页数：5

共 44 条

[1] Flavonoid structure-activity studies identify 6-prenyichrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2 [J].